Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

High expression of ezrin predicts poor prognosis in uterine cervical cancer

Authors: Jienan Kong, Yan Li, Shuangping Liu, Haidan Jin, Yongjun Shang, Chengshi Quan, Yulin Li, Zhenhua Lin

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

Ezrin, a member of the ezrin/radixin/moesin (ERM) protein family, plays a pivotal role in tumor invasion and metastasis. This study is aimed to investigate the clinicopathological significance of upregulated ezrin protein expression in uterine cervical cancers.

Methods

Immunohistochemical staining of ezrin protein was performed on uterine cervical cancer specimens from 235 patients. For comparison, 239 cases of cervical intraepithelial neoplasia (CIN), 17 cases of cervical glandular intraepithelial neoplasia (CGIN) and 52 normal cervix samples were also included. qRT-PCR was performed on fresh tissues to detect ezrin mRNA expression levels. HPV infection statuses were genotyped by oligonucleotide microarray, and 10-year survival rates were calculated using the Kaplan-Meier method for 109 cervical cancer patients.

Results

Apical membranous distribution of ezrin protein was only observed in normal cervical glands, while perinuclear staining was only observed in cervical cancers. Strong cytoplasmic and diffuse localization of ezrin were frequently seen in the cervical cancers compared with the normal counterparts. Furthermore, this strongly positive ezrin expression was significantly higher in cervical cancers than in CIN, CGIN, and normal cervical epithelia. Ezrin overexpression was closely related with poor differentiation, late stage, and lymph node metastasis. Additionally, ezrin overexpression was associated with lower 10-year survival rate for patients with early stage cervical cancer, but not for patients with advanced stage.

Conclusions

Aberrant localization and overexpression of ezrin might be an independent effective biomarker for prognostic evaluation of cervical cancers.
Appendix
Available only for authorised users
Literature
1.
Li Q, Gao H, Xu H, Wang X, Pan Y, Hao F, Qiu X, Stoecker M, Wang E, Wang E: Expression of Ezrin correlates with malignant phenotype of lung cancer, and in vitro knockdown of Ezrin reverses the aggressive biological behavior of lung cancer cells. Tumour Biol. 2012, 33 (5): 1493-504.CrossRefPubMed
2.
Neisch AL, Fehon RG: Ezrin, Radixin and Moesin: key regulators of membrane–cortex interactions and signaling. Curr Opin Cell Biol. 2011, 23 (4): 377-382.CrossRefPubMedPubMedCentral
3.
Huang HY, Li CF, Fang FM, Tsai JW, Li SH, Lee YT, Wei HM: Prognostic implication of Ezrin overexpression in myxofibrosarcomas. Ann Surg Oncol. 2010, 17 (12): 3212-3219.CrossRefPubMed
4.
5.
Bretscher A, Edwards K, Fehon RG: ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol. 2002, 3 (8): 586-599.CrossRefPubMed
6.
Gautreau A, Louvard D, Arpin M: Morphogenic effects of ezrin require a phosphorylation-induced transition from oligomers to monomers at the plasma membrane. J Cell Biol. 2000, 150 (1): 193-203.CrossRefPubMedPubMedCentral
7.
Hiscox S, Jiang WG: Ezrin regulates cell-cell and cell-matrix adhesion, a possible role with E-cadherin/beta-catenin. J Cell Sci. 1999, 18: 3081-3090.
8.
Ohtani K, Sakamoto H, Rutherford T, Chen Z, Satoh K, Naftolin F: Ezrin, a membrane–cytoskeletal linking protein, is involved in the process of invasion of endometrial cancer cells. Cancer Lett. 1999, 147 (1–2): 31-38.CrossRefPubMed
9.
Yasuoka H, Tsujimoto M, Inagaki M, Kodama R, Tsuji H, Iwahashi Y, Mabuchi Y, Ino K, Sanke T, Nakamura Y: Clinicopathological significance of podocalyxin and phosphorylated ezrin in uterine endometrioid adenocarcinoma. J Clin Pathol. 2012, 65 (5): 399-402.CrossRefPubMed
10.
Köbel M, Gradhand E, Zeng K, Schmitt WD, Kriese K, Lantzsch T, Wolters M, Dittmer J, Strauss HG, Thomssen C, Hauptmann S: Ezrin promotes ovarian carcinoma cell invasion and its retained expression predicts poor prognosis of ovarian carcinoma. Int J Gynecol Pathol. 2006, 25 (2): 121-130.CrossRefPubMed
11.
Kocher HM, Sandle J, Mirza TA, Li NF, Hart IR: Ezrin interacts with cortactin to form podosomal rosettes in pancreatic cancer cells. Gut. 2009, 58 (2): 271-284.CrossRefPubMed
12.
Cui Y, Li T, Zhang D, Han J: Expression of Ezrin and phosphorylated Ezrin (pEzrin) in pancreatic ductal adenocarcinoma. Cancer Invest. 2010, 28 (3): 242-247.CrossRefPubMed
13.
Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, Yeung C, Gorlick R, Hewitt SM, Helman LJ: The membrane-cytoskeleton linker Ezrin is necessary for osteosarcoma metastasis. Nat Med. 2004, 10 (2): 182-186.CrossRefPubMed
14.
Khanna C, Khan J, Nguyen P, Prehn J, Caylor J, Yeung C, Trepel J, Meltzer P, Helman L: Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res. 2001, 61 (9): 3750-3759.PubMed
15.
Li Q, Wu M, Wang H, Xu G, Zhu T, Zhang Y, Liu P, Song A, Gang C, Han Z, Zhou J, Meng L, Lu Y, Wang S, Ma D: Ezrin silencing by small hairpin RNA reverses metastatic behaviors of human breast cancer cells. Cancer Lett. 2008, 261 (1): 55-63.CrossRefPubMed
16.
Tavassoli FA, Devilee P: World Health Organization Classification of Tumors, Pathology & Genetics Tumours of the Breast and Female Genital Organs. 2003, Lyon: IARC Press
17.
Elzagheid A, Korkeila E, Bendardaf R, Buhmeida A, Heikkilä S, Vaheri A, Syrjänen K, Pyrhönen S, Carpén O: Intense cytoplasmic ezrin immunoreactivity predicts poor survival in colorectal cancer. Hum Pathol. 2008, 39 (12): 1737-1743.CrossRefPubMed
18.
19.
Zhao Y, Lin H, Shen D, Xuan Y, Lin Z: Distribution of HPV genotypes in uterine cervical lesions in Yanbian, northern China. Pathol Int. 2008, 58 (10): 643-647.CrossRefPubMed
20.
21.
22.
Das P, Thomas A, Mahantshetty U, Shrivastava SK, Deodhar K, Mulherkar R: HPV genotyping and site of viral integration in cervical cancers in Indian women. PLoS One. 2012, 7 (7): e41012-CrossRefPubMedPubMedCentral
23.
Steeg PS: Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006, 12 (8): 895-904.CrossRefPubMed
24.
Fievet B, Louvard D, Arpin M: ERM proteins in epithelial cell organization and functions. Biochim Biophys Acta. 2007, 1773 (5): 653-660.CrossRefPubMed
25.
Arslan AA, Silvera D, Arju R, Giashuddin S, Belitskaya-Levy I, Formenti SC, Schneider RJ: Atypical ezrin localization as a marker of locally advanced breast cancer. Breast Cancer Res Treat. 2012, 134 (3): 981-988.CrossRefPubMed
26.
Yu Y, Khan J, Khanna C, Helman L, Meltzer PS, Merlino G: Expression profiling identifies the cytoskeletal organizer Ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med. 2004, 10 (2): 175-181.CrossRefPubMed
27.
Sarrió D, Rodríguez-Pinilla SM, Dotor A, Calero F, Hardisson D, Palacios J: Abnormal ezrin localization is associated with clinicopathological features in invasive breast carcinomas. Breast Cancer Res Treat. 2006, 98 (1): 71-79.CrossRefPubMed
28.
Cui Y, Wu J, Zong M, Song G, Jia Q, Jiang J, Han J: Proteomic profiling in pancreatic cancer with and without lymph node metastasis. Int J Cancer. 2009, 124 (7): 1614-1621.CrossRefPubMed
29.
Tan J, Zhang C, Qian J: Expression and significance of Six1 and Ezrin in cervical cancer tissue. Tumor Biol. 2011, 32 (6): 1241-1247.CrossRef
30.
Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N EngI J Med. 2003, 348 (6): 518-527.CrossRef
31.
Schmitt M, Bravo IG, Snijders PJ, Gissmann L, Pawlita M, Waterboer T: Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol. 2006, 44 (2): 504-512.CrossRefPubMedPubMedCentral
32.
Guo M, Sneige N, Silva EG, Jan YJ, Cogdell DE, Lin E, Luthra R, Zhang W: Distribution and viral load of eight oncogenic types of human papillomavirus (HPV) and HPV 16 integration status in cervical intraepithelial neoplasia and carcinoma. Mod Pathol. 2007, 20 (2): 256-266.CrossRefPubMed
33.
Krul EJ, Van De Vijver MJ, Schuuring E, Van Kanten RW, Peters AA, Fleuren GJ: Human papillomavirus in malignant cervical lesions in Surinam, a high-risk country, compared to the Netherlands, a low-risk country. Int J Gynecol Cancer. 1999, 9 (3): 206-211.CrossRefPubMed
34.
Lin ZH, Shen XH, Jin Z, Kim Y, Lee E, Kim H, Kim I: Human papillomavirus genotyping by oligonucleotide microarray and p16 expression in uterine cervical intraepithelial neoplasm and in invasive carcinoma in Korean women. Pathol Int. 2005, 55 (8): 491-496.CrossRefPubMed
35.
Qian K, Pietilä T, Rönty M, Michon F, Frilander MJ, Ritari J, Tarkkanen J, Paulín L, Auvinen P, Auvinen E: Identification and Validation of Human Papillomavirus Encoded microRNAs. PLoS One. 2013, 8 (7): e70202-CrossRefPubMedPubMedCentral
36.
Greco D, Kivi N, Qian K, Leivonen SK, Auvinen P, Auvinen E: Human papillomavirus 16 E5 modulates the expression of host microRNAs. PLoS One. 2011, 6 (7): e21646-CrossRefPubMedPubMedCentral
37.
Auvinen E, Carpen O, Korpela T, Ronty M, Vaheri A, Tarkkanen J: Altered expression of ezrin, E-Cadherin and β-Catenin in cervical neoplasia. Neoplasma. 2013, 60 (1): 56-61.CrossRefPubMed
38.
Geiger T, Sabanay H, Kravchenko-Balasha N, Geiger B, Levitzki A: Anomalous features of EMT during keratinocyte transformation. PLoS One. 2008, 3 (2): e1574-CrossRefPubMedPubMedCentral
Metadata
Title
High expression of ezrin predicts poor prognosis in uterine cervical cancer
Authors
Jienan Kong
Yan Li
Shuangping Liu
Haidan Jin
Yongjun Shang
Chengshi Quan
Yulin Li
Zhenhua Lin
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-520

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue

Research article

Elevated cyclin B2 expression in invasive breast carcinoma is associated with unfavorable clinical outcome

Research article

Preoperative neutrophil/lymphocyte ratio predicts overall survival but does not predict recurrence or cancer-specific survival after curative resection of node-positive colorectal cancer

Research article

Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study

Research article

Claudin 1 expression in basal-like breast cancer is related to patient age

Research article

Trends of risk classification and primary therapy for Japanese patients with prostate cancer in Nara Uro-Oncological Research Group (NUORG)–a comparison between 2004-2006 and 2007-2009

Research article

Increased phosphorylation of histone H3 at serine 10 is involved in Epstein-Barr virus latent membrane protein-1-induced carcinogenesis of nasopharyngeal carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits